WHO WE ARE?
We are a pure play Contract Development and Manufacturing Organization (CDMO) specialized in the development and manufacturing of gene therapies, oncolytic viruses and vaccine candidates. Our teams of experts based on our 3 sites, in Europe and in the US, are devoted to support innovative projects and help to reduce overall timelines and costs.
Our mission is to provide GMP viral vectors from early-stage to market, contributing to the success of our clients’ immunotherapy and gene therapy innovations.
We offer a broad range of viral vectors, including AAV, LVV, MVA, Poxvirus, Vaccinia, Measles, and more.
Our CDMO services include manufacturing of bulk drug substance, fill-finish of drug products, process and assay development, bioanalytical testing and regulatory support.
We place the client at the heart of everything we do. We implement strategies to achieve Best-class Customer Experience. A team of experts is dedicated to your project to provide you the best innovative solutions adapted to your needs in order to meet your expectations.
- 1994
first viral vector facility in Europe - 3
facilities
(France & USA) - ~320
employees - >25
years of experience
in viral vectors
(manufacturing) - Fill & up to
10 000
vials/batch
OUR HISTORY
ABL is a pure play Contract Development and Manufacturing Organization (CDMO) specialized in the development and manufacturing of oncolytic viruses, gene therapies, and vaccine candidates based on viral vectors.
We are grounded in the Mérieux family’s legacy of biology and vaccine expertise, dating back to 1897.
As a pioneer, we have been developing and producing virus vector since 1990s. We started with Pox Virus, MVA, Vaccinia and oncolytic viruses to support our clients’ clinical trials with the final goal of fighting against smallpox and several types of cancer.
We have continuously added new viruses within our portfolio, including manufacturing of AAVs in 2016 through adherent and suspension processes. Based on this strong expertise in virology and cell culture, in 2022 we decided to develop our high predictable yield and versatile AAV platform to manufacture different serotypes.
More than ever, our vision is to contribute to a long-term public health vision where Bio-Industry has a central role for a healthier world.
Today, ABL is fully owned by Institut Mérieux.
OUR MISSION & VISION
OUR MISSION: By accelerating our Customer’s life-saving innovations, ABL is contributing to a long-term public health vision where Bio-Industry has a central role for a healthier world.
OUR VISION: Become a leading global biomanufacturing CDMO trusted to deliver innovation and excellence. We empower people. We foster an entrepreneurial culture. We commit to sustainability.
WHAT DO WE OFFER?
ABL
Your solution provider
Developing and manufacturing viral vectors for more than 25 years
Read more
Dedicated project management
Read more
Effective quality control capabilities essential for your success
Read more
Flexibility reflected within our contracts
Read more
Customer centricity
Read more
Talented teams to deliver the highest level of services
Read more
OUR LEADERSHIP TEAM
Thierry VAN NIEUWENHOVE
Chief Executive Officer
Aymeric CANU
Chief Finance Officer
Nicolas SALAVIN
Chief Technology Officer
Arnaud MARTIN
Global Head Business
Development & Sales
Béatrice BARBIER
Legal / Compliance Director
Stéphanie COLLOUD
Lyon Site Director
Christian GUBIANI
Strasbourg Site Director
Estelle AZOULAY
Human Ressources Director
Marykay MARCHIGIANI
General Manager / Chief
Operations Officer ABL Inc
Justine CHABROL
Head of Communications & CSR